Independent study confirms that the C-RAD Sentinel™ enables increase in patient throughput while reducing dose to healthy tissue

Press release 2010-06-21                                                        

Independent study confirms that the C-RAD Sentinel™ enables increase in patient 
throughput while reducing dose to healthy tissue                                

C-RAD AB with its three fully owned subsidiaries develops new and innovative    
solutions for the use in advanced radiation therapy. A recent study from the    
University Hospital in Lund, Sweden, confirms the clinical benefits of the      
company's Sentinel™ system.                                                     
The C-RAD Sentinel™ is an advanced laser-camera based system that can be used   
for multiple applications within the field of radiation therapy. The system can 
within a few seconds detect a patient misalignment and can also monitor the     
patient for motion during treatment.                                            
The University Hospital in Lund, Sweden, has during the first few months of 2010
evaluated the Sentinel™ system for use on one of their treatment machines. The  
aim was to increase the patient throughput without compromising positioning     
accuracy. The results have been presented at a European meeting for radiation   
therapy professionals.                                                          
In the performed study, the Sentinel™ system was used in parallel with the      
on-board imaging system (based on ionizing radiation) to verify the patient     
position before treatment. The measurements from both systems were then         
compared.                                                                       
According to the published results, the accuracy of the Sentinel™ system was so 
high that the on-board imaging system would only need to be used for a few of   
the treatment fraction as an additional verification, while the Sentinel™ would 
be used for the remaining fractions. This is estimated to increase the patient  
throughput by approximately 50%-75% while decreasing the patient dose due to    
imaging by approximately 70%.                                                   
The end result is more patients treated per day, with maintained accuracy and   
reduced dose. Following the successful evaluation, the hospital has now         
incorporated the system in the daily clinical routine.                          

Erik Hedlund, CEO, C-RAD AB:                                                    
“The result from Lund provides an independent confirmation that the Sentinel™   
concept is highly clinically relevant, and also shows the potential of advancing
the state-of-the-art in radiation therapy when it comes to the important matters
of increasing patient throughput and reducing dose to healthy tissue. As a first
indication of the market potential, we have already noted a strong interest from
prospective customers and industrial partners. “                                

For further information:                                                        
Erik Hedlund, CEO C-RAD AB, Phone +46-18-666931, E-mail erik.hedlund@c-rad.se   




About C-RAD AB                                                                  
C-RAD develops new and innovative solutions for the use in advanced radiation   
therapy. The company group of C-RAD offers products and solutions for patient   
positioning, tumor localization and radiation treatment systems. End users are  
radiation therapy clinics worldwide. All product development is conducted in    
three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD
Innovation AB. C-RAD Imaging AB is located in Östersund while the other         
companies are located in Uppsala. Numbers of employees are currently 19 people. 
The activity in C-RAD AB originates in research and development at the          
Karolinska Institutet in Solna and the The Royal Institute of Technology in     
Stockholm. Sales of the company's first product, the Sentinel system, started in
autumn 2006. Co-operation agreements have been signed with the radiation therapy
company Elekta and the Belgian company IBA. On major markets in Europe, North   
America and East Asia the company is represented by distributors normally       
specialized in radiation therapy.                                               
C-RAD was since July 2007 listed at Aktietorget. From 8 March 2010 C-RAD is     
traded at OMX First North Premier.